{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:15:12Z","timestamp":1765527312450,"version":"3.48.0"},"reference-count":46,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_hmbci-2019-0048_s_999_w2aab3b7c22b1b6b1aab1c15b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hyperandrogenemic polycystic ovary syndrome (PCOS) may have occult corticosteroidogenic enzyme abnormalities. The current study compares the activities of 11\u03b2-hydroxylase between normoandrogenemic PCOS (NA-PCOS) and hyperandrogenemic PCOS (HA-PCOS) phenotypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2019-0048_s_998_w2aab3b7c22b1b6b1aab1c15b2Aa\">\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Anthropometric, and biochemical variables were compared between normal cycling women [n = 272] and those with PCOS [n = 453]; either normoandrogenemic [n = 98] or hyperandrogenemic [n = 355]. Univariate and multivariate logistic regression analyses were performed using 11\u03b2-hydroxylase enzyme activity as the criterion variable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2019-0048_s_997_w2aab3b7c22b1b6b1aab1c15b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      11\u03b2-Hydroxylase enzyme activity tended to be slightly higher in both PCOS subgroups and did not change with ethnicity. Using univariate logistic regression, 11\u03b2-hydroxylase activity in controls was associated with dehydroepiandrosterone, insulin, homeostatic model for insulin resistance (HOMA-IR), and high-density lipoprotein cholesterol (HDL-C). In NA-PCOS women  the activity of 11\u03b2-hydroxylase was associated with estradiol (E\n                      <jats:sub>2<\/jats:sub>\n                      ), androstenedione (A4), and androstenedione\/dehydroepiandrosterone ratio; in the hyperandrogenemic (HA-PCOS) group, 11\u03b2-hydroxylase activity associated with sex-hormone binding globulin (SHBG), 17-hydroxypregnenolone (17-OHPE), fasting glucose, and \u03b2-cell activity. After multivariate logistic regression, androstenedione\/dehydroepiandrosterone ratio, and \u03b2-cell activity were the best predictors of 11\u03b2-hydroxylase activity in controls; in NA-PCOS group only androstenedione\/dehydroepiandrosterone ratio was confirmed as a significant predictor of 11\u03b2-hydroxylase activity, and in HA-PCOS patients, 17-OHPE and \u03b2-cell activity demonstrated to be significant predictors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2019-0048_s_996_w2aab3b7c22b1b6b1aab1c15b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>11\u03b2-Hydroxylase activity was equal in different ethnicities. The prevalence of decreased 11\u03b2-hydroxylase activity was higher in the HA-PCOS phenotype. 17-OHPE, and \u03b2-cell function are significant predictors of 11\u03b2-hydroxylase activity in HA-PCOS subjects. These findings may help to identify which PCOS patient would have benefit in measuring 11-deoxycortisol (compound S) and 11\u03b2-hydroxylase enzyme activity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/hmbci-2019-0048","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T04:01:16Z","timestamp":1578628876000},"source":"Crossref","is-referenced-by-count":1,"title":["Exploring the activity of the enzyme 11\u03b2-hydroxylase in the polycystic ovary syndrome"],"prefix":"10.1515","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1292-2515","authenticated-orcid":false,"given":"Sebasti\u00e3o","family":"Freitas de Medeiros","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, Medical School , Federal University of Mato Grosso , Zip Code 78 043 306, Cuiab\u00e1 , MT , Brazil , Phone: +55 65 3322 2017, +55 65 99981 0474"},{"name":"Tropical Institute of Reproductive Medicine , Cuiab\u00e1, MT , Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Camila Antunes","family":"Angelo","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Medical School , Federal University of Mato Grosso , Cuiab\u00e1 , MT , Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matheus Ant\u00f4nio","family":"Souto de Medeiros","sequence":"additional","affiliation":[{"name":"Tropical Institute of Reproductive Medicine , Cuiab\u00e1, MT , Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruna Barcelo","family":"Barbosa","sequence":"additional","affiliation":[{"name":"Tropical Institute of Reproductive Medicine , Cuiab\u00e1, MT , Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rcia Marly Winck","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Tropical Institute of Reproductive Medicine , Cuiab\u00e1, MT , Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2020,1,10]]},"reference":[{"key":"2025121207192860700_j_hmbci-2019-0048_ref_001_w2aab3b7c22b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obest Gynecol. 1935;29:181\u201391.","DOI":"10.1016\/S0002-9378(15)30642-6"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_002_w2aab3b7c22b1b6b1ab2b2b2Aa","unstructured":"Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif AG, Haseltine F, editors. Polycystic ovary syndrome. Baston: Blackwall Scientific; 1992: 377\u201384."},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_003_w2aab3b7c22b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"The Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19\u201325.","DOI":"10.1016\/j.fertnstert.2003.10.004"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_004_w2aab3b7c22b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Androgen Excess Society. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91:4237\u201345.","DOI":"10.1210\/jc.2006-0178"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_005_w2aab3b7c22b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745\u20139.","DOI":"10.1210\/jc.2003-032046"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_006_w2aab3b7c22b1b6b1ab2b2b6Aa","unstructured":"de Medeiros SF, Yamamoto MMW, de Medeiros MAS, Barbosa JS, Norman RJ. Should subclinical hypothyroidism be an exclusion criterion for the diagnosis of polycystic ovary syndrome? J Reprod Infertil. 2017a;18:242\u201350."},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_007_w2aab3b7c22b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Payne HA, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev. 2004;25:947\u201370.","DOI":"10.1210\/er.2003-0030"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_008_w2aab3b7c22b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"de Medeiros SF, Gil-Junior AB, Barbosa JS, Isa\u00edas ED, Yamamoto MMW. New insights into steroidogenesis in normo-and hyperandrogenic polycystic ovary syndrome patients. Arq Bras Endocrinol Metabol. 2013;57:437\u201344.","DOI":"10.1590\/S0004-27302013000600005"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_009_w2aab3b7c22b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Carmina E, Malizia G, Pagano M, Janni A. Prevalence of late-onset 11 beta-hydroxylase deficiency in hirsute patients. J Endocrinol Invest. 1988;11:595\u20138.","DOI":"10.1007\/BF03350188"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_010_w2aab3b7c22b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Sahin Y, Kele\u015ftimur F. 17-Hydroxyprogesterone responses to gonadotrophin-releasing hormone agonist buserelin and adrenocorticotrophin in polycystic ovary syndrome: investigation of adrenal and ovarian cytochrome. 1997;12:910\u201313.","DOI":"10.1093\/humrep\/12.5.910"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_011_w2aab3b7c22b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Gibson M, Lackritz R, Schiff I, Tulchinsky D. Abnormal adrenal responses to adrenocorticotropic hormone in hyperandrogenic women. Fertil Steril. 1980;33:43\u201348.","DOI":"10.1016\/S0015-0282(16)44475-4"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_012_w2aab3b7c22b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Turcu AF, Auchus RJ. Clinical significance of 11-oxygenated androgens. Curr Opin Endocrinol Diabetes Obes. 2017;24:252\u20139.","DOI":"10.1097\/MED.0000000000000334"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_013_w2aab3b7c22b1b6b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Ditkoff EC, Fruzzetti F, Chang L. The impact of estrogen on adrenal androgen sensitivity and secretion in polycystic ovary syndrome. J Clin Endocrinol Metab. 1995;80:603\u20137.","DOI":"10.1210\/jcem.80.2.7852527"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_014_w2aab3b7c22b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"de Medeiros SF, Yamamoto MMW. Differential activity of the corticosteroidogenic enzymes in normal cycling women and women with polycystic ovary syndrome. Rev Endocrinol Metab Disord. 2019;20:3\u201313.","DOI":"10.1007\/s11154-019-09482-3"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_015_w2aab3b7c22b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"de Medeiros SF, Barbosa JS, Yamamoto MMW. Comparison of steroidogenic pathways among normoandrogenic and hyperandrogenic polycystic ovary syndrome patients and normal cycling women. J Obstet Gynaecol Res. 2015;41:254\u201363.","DOI":"10.1111\/jog.12524"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_016_w2aab3b7c22b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"de Medeiros SF, Ormond CM, de Medeiros MAS, de Souza Santos N, Banhara CR, Yamamoto MMW. Metabolic and endocrine connections of 17-hydroxypregnenolone in polycystic ovary syndrome women. Endocr Connect. 2017b;6:479\u201388.","DOI":"10.1530\/EC-17-0151"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_017_w2aab3b7c22b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 2 Classification and diagnosis of diabetes. Am Diabetes Assoc. 2017;40(Suppl 1):S11\u2013S24.","DOI":"10.2337\/dc17-S005"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_018_w2aab3b7c22b1b6b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Geloneze B, Vasques AC, Stabe CF. BRASMS Investigators, HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome: Brazilian Metabolic Syndrome Study (BRAMS). Arq Bras Endocrinol Metab. 2009;53:281\u20137.","DOI":"10.1590\/S0004-27302009000200020"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_019_w2aab3b7c22b1b6b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412\u20139.","DOI":"10.1007\/BF00280883"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_020_w2aab3b7c22b1b6b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"Kushnir MM, Rockwood AL, Roberts WL, Pattison EG, Owen WE, Bunker AM, et al. Development and performance evaluation of a tandem mass spectrometry assay for 4 adrenal steroids. Clin Chem. 2006;52:1559\u201367.","DOI":"10.1373\/clinchem.2006.068445"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_021_w2aab3b7c22b1b6b1ab2b2c21Aa","doi-asserted-by":"crossref","unstructured":"Legro RS, Schlaff WD, Diamond MP. Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism. J Clin Endocrinol Metab. 2010;95:5305\u201313.","DOI":"10.1210\/jc.2010-1123"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_022_w2aab3b7c22b1b6b1ab2b2c22Aa","doi-asserted-by":"crossref","unstructured":"Hicks RA, Yee JK, Mao CS, Graham S, Kharrazi M, Lorey F, et al. Precursor-to-product ratios reflect biochemical phenotype in congenital adrenal hyperplasia. Metabolomics. 2014;10:123\u201331.","DOI":"10.1007\/s11306-013-0558-1"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_023_w2aab3b7c22b1b6b1ab2b2c23Aa","doi-asserted-by":"crossref","unstructured":"Tieh PY, Yee JKW, Hicks RA, Catherine Shring-May Mao MD, Paul Lee W-N. Utility of a precursor-to-product ratio in the evaluation of presumptive positives in newborn screening of congenital adrenal hyperplasia. J Perinatol. 2017;37:283\u20137.","DOI":"10.1038\/jp.2016.223"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_024_w2aab3b7c22b1b6b1ab2b2c24Aa","doi-asserted-by":"crossref","unstructured":"de Medeiros SF, Yamamoto MMW, Bueno HB, Belizario D, Barbosa JS. Prevalence of elevated glycated hemoglobin concentrations in the polycystic ovary syndrome: anthropometrical and metabolic relationship in Amazonian women. J Clin Med Res. 2014;6:6278\u201386.","DOI":"10.14740\/jocmr1829w"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_025_w2aab3b7c22b1b6b1ab2b2c25Aa","doi-asserted-by":"crossref","unstructured":"Gambineri A, Forlani G, Munarini A, Tomassoni F, Cognigni GE, Ciampaglia W, et al. Increased clearance of cortisol by 5beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome. J Endocrinol Invest. 2009;32:210\u20138.","DOI":"10.1007\/BF03346454"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_026_w2aab3b7c22b1b6b1ab2b2c26Aa","doi-asserted-by":"crossref","unstructured":"Blumenfeld Z, Kaidar G, Zuckerman-Levin N, Dumin E, Knopf C, Hochberg Z. Cortisol-metabolizing enzymes in polycystic ovary syndrome. Clin Med Insights Reprod Health. 2016;10:9\u201313.","DOI":"10.4137\/CMRH.S35567"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_027_w2aab3b7c22b1b6b1ab2b2c27Aa","doi-asserted-by":"crossref","unstructured":"Deng W, Liu X, Chen X, Wei G, Zeng T, Xie L, Jian-xin Z. A comparison of the climates of the medieval climate anomaly little ice age, and current warm period reconstructed using coral records from the northern South China Sea. J Geophys Res. 2017;122:264\u201375.","DOI":"10.1002\/2016JC012458"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_028_w2aab3b7c22b1b6b1ab2b2c28Aa","doi-asserted-by":"crossref","unstructured":"Sahin Y, Kelestimur F. The frequency of late-onset 21-hydroxylase and CYP11B1 deficiency in women with polycystic ovary syndrome. Eur J Endocrine. 1997;137:670\u20134.","DOI":"10.1530\/eje.0.1370670"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_029_w2aab3b7c22b1b6b1ab2b2c29Aa","doi-asserted-by":"crossref","unstructured":"Rothman MS, Carlson NE, Xu M, Wang C, Swerdloff R, Lee P, et al. Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography-tandem mass spectrometry. Steroids. 2011;76:177\u201382.","DOI":"10.1016\/j.steroids.2010.10.010"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_030_w2aab3b7c22b1b6b1ab2b2c30Aa","doi-asserted-by":"crossref","unstructured":"Pall M, Azziz R, Beires J, Pignatelli D. The phenotype of hirsute women: a comparison of polycystic ovary syndrome and 21-hydroxylase-deficient nonclassic adrenal hyperplasia. Fertil Steril. 2010;94:684\u20139.","DOI":"10.1016\/j.fertnstert.2009.06.025"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_031_w2aab3b7c22b1b6b1ab2b2c31Aa","doi-asserted-by":"crossref","unstructured":"Carmina E, Gonzalez F, Chang L, Lobo RA. Reassessment of adrenal androgen secretion in women with polycystic ovary syndrome. Obstet Gynecol. 1995;85:971\u20136.","DOI":"10.1016\/0029-7844(95)00065-Y"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_032_w2aab3b7c22b1b6b1ab2b2c32Aa","doi-asserted-by":"crossref","unstructured":"Doi SA, Al-Zaid M, Towers PA, Scott CJ, AI-Shoumer KA. Steroidogenic alterations and adrenal androgen excess in PCOS. Steroids. 2006;71:751\u20139.","DOI":"10.1016\/j.steroids.2006.05.005"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_033_w2aab3b7c22b1b6b1ab2b2c33Aa","doi-asserted-by":"crossref","unstructured":"Trakakis E, Rizos D, Loghis C. The prevalence of non-classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency in Greek women with hirsutism and polycystic ovary syndrome. Endocr J. 2008;55:33\u20139.","DOI":"10.1507\/endocrj.K07-053"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_034_w2aab3b7c22b1b6b1ab2b2c34Aa","doi-asserted-by":"crossref","unstructured":"Sharma DC, Forchielli E, Dorfman RI. Inhibition of enzymatic steroid 11\u03b2-hydroxylation by androgens. J Biol Chem. 1963;238:572\u20135.","DOI":"10.1016\/S0021-9258(18)81300-X"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_035_w2aab3b7c22b1b6b1ab2b2c35Aa","doi-asserted-by":"crossref","unstructured":"Gillis D, Speiser P, Zhou Z, Rosler A. Combined 21-hydroxylase deficiency: patients report and molecular basis. J Pediatr Endocrinol Metab. 2000;13:945\u20139.","DOI":"10.1515\/JPEM.2000.13.7.945"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_036_w2aab3b7c22b1b6b1ab2b2c36Aa","doi-asserted-by":"crossref","unstructured":"Rosenfield RL, Barnes RB, Cara JF. Dysregulation of cytochrome P450c 17 alpha as a cause of polycystic ovary syndrome. Fertil Steril. 1990;53:785\u201391.","DOI":"10.1016\/S0015-0282(16)53510-9"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_037_w2aab3b7c22b1b6b1ab2b2c37Aa","doi-asserted-by":"crossref","unstructured":"Atmaca A, Dagdelen S, Erbas T. Follow-up of pregnancy in acromegalic women: different presentations and outcomes. Exp Clin Endocrinol Diabetes. 2006;114:135\u20139.","DOI":"10.1055\/s-2005-873004"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_038_w2aab3b7c22b1b6b1ab2b2c38Aa","doi-asserted-by":"crossref","unstructured":"Guthrie GP Jr, Wilson EA, Quillen DL, Jawad MJ. Adrenal androgen excess and defective 11\u03b2-hydroxylation in women with idiopathic hirsutism. Arch Intern Med. 1982;142:729\u201335.","DOI":"10.1001\/archinte.1982.00340170085017"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_039_w2aab3b7c22b1b6b1ab2b2c39Aa","doi-asserted-by":"crossref","unstructured":"Bouallouche A, Brerault JL, Fiet J, Julien R, Vermeulen C, Cathelineau G. Evidence for adrenal and\/or ovarian dysfunction as a possible etiology of idiopathic hirsutism. Am J Obstet Gynecol. 1983;147:57\u201363.","DOI":"10.1016\/0002-9378(83)90084-4"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_040_w2aab3b7c22b1b6b1ab2b2c40Aa","doi-asserted-by":"crossref","unstructured":"Eldar-Geva T, Hurwitz A, Vecsei P, Palti Z, Milwidsky A, Rosler A. Secondary biosynthetic defects in women with late-onset congenital adrenal hyperplasia. Engl J Med. 1990;32:855\u201363.","DOI":"10.1056\/NEJM199009273231302"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_041_w2aab3b7c22b1b6b1ab2b2c41Aa","doi-asserted-by":"crossref","unstructured":"Kele\u015ftimur F, Sahin Y, Ayata D, Tutu\u015f A. The prevalence of non-classic adrenal hyperplasia due to 11 beta-hydroxylase deficiency among hirsute women in a Turkish population. Clin Endocrinol. 1996;45:381\u20134.","DOI":"10.1046\/j.1365-2265.1996.8150825.x"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_042_w2aab3b7c22b1b6b1ab2b2c42Aa","doi-asserted-by":"crossref","unstructured":"Willenberg HS, Bahlo M, Schott M, Wertenbruch T, Feldkamp J, Scherbaum WA. Helpful diagnostic markers of steroidogenesis for defining hyperandrogenemia in hirsute women. Steroids. 2008;73:41\u20136.","DOI":"10.1016\/j.steroids.2007.08.009"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_043_w2aab3b7c22b1b6b1ab2b2c43Aa","doi-asserted-by":"crossref","unstructured":"Dolfing JG, Tucker KE, Lem CM, Uittenbogaart J, Verzijl JC, Schweitzer DH. Low 11-deoxycortisol to cortisol conversion reflects extra-adrenal factors in the majority of women with normo-gonadotrophic normo-estrogenic infertility. Human Reprod. 2003;18:333\u20137.","DOI":"10.1093\/humrep\/deg082"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_044_w2aab3b7c22b1b6b1ab2b2c44Aa","doi-asserted-by":"crossref","unstructured":"Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab. 2005;90:2545\u20139.","DOI":"10.1210\/jc.2004-2279"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_045_w2aab3b7c22b1b6b1ab2b2c45Aa","doi-asserted-by":"crossref","unstructured":"Baptiste CG, Marie-Claude B, Trottier A, Baillargeon JP. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2010;122:42\u201352.","DOI":"10.1016\/j.jsbmb.2009.12.010"},{"key":"2025121207192860700_j_hmbci-2019-0048_ref_046_w2aab3b7c22b1b6b1ab2b2c46Aa","doi-asserted-by":"crossref","unstructured":"Mullins LJ, Peter A, Wrobel N, McNeilly JR, McNeilly AS, Al-Dujaili EA, et al. Cyp11b1 null mouse, a model of congenital adrenal hyperplasia. J Biol Chem. 2009;284:3925\u2013393.","DOI":"10.1074\/jbc.M805081200"}],"container-title":["Hormone Molecular Biology and Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/hmbci\/ahead-of-print\/article-10.1515-hmbci-2019-0048\/article-10.1515-hmbci-2019-0048.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2019-0048\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2019-0048\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:10:42Z","timestamp":1765527042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2019-0048\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,10]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,3,13]]},"published-print":{"date-parts":[[2020,7,24]]}},"alternative-id":["10.1515\/hmbci-2019-0048"],"URL":"https:\/\/doi.org\/10.1515\/hmbci-2019-0048","relation":{},"ISSN":["1868-1891","1868-1883"],"issn-type":[{"type":"electronic","value":"1868-1891"},{"type":"print","value":"1868-1883"}],"subject":[],"published":{"date-parts":[[2020,1,10]]},"article-number":"20190048"}}